Penpulimab
- Generic Name
- Penpulimab
- Drug Type
- Biotech
- CAS Number
- 2350298-92-7
- Unique Ingredient Identifier
- IBS1BZ4E4I
- Indication
适用于至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤成人患者。
AK129 Combination Therapy for Advanced Solid Tumors
- Conditions
- Non-small Cell Lung Cancer Stage IIIB/IVHead and Neck Squamous Cell Carcinoma (HNSCC)Colorectal AdenocarcinomaAdvanced Solid Tumors
- Interventions
- Drug: ChemotherapyDrug: AK129(dose 1)Drug: Cis-platinumDrug: 5-FU (5-fluorouracil)Drug: AK129(dose 2)Drug: AK129(RP2D)
- First Posted Date
- 2025-04-24
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Akeso
- Target Recruit Count
- 230
- Registration Number
- NCT06943820
- Locations
- 🇨🇳
Liaoning Cancer Hospital, Shenyang, Liaoning, China
Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C
- Conditions
- Advanced Pancreatic Cancer
- Interventions
- First Posted Date
- 2025-02-12
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 72
- Registration Number
- NCT06821503
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Cancer Hospital Chinese Academy of Medical Science, BeiJing, Beijing, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL
- Conditions
- Diffuse Large B Cell Lymphoma
- Interventions
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-07-24
- Target Recruit Count
- 528
- Registration Number
- NCT06516978
A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2024-06-05
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Lei Liu
- Target Recruit Count
- 90
- Registration Number
- NCT06444009
- Locations
- 🇨🇳
West China Hospital, Chengdu, Sichuan, China
Clinical Study of TQB2223 Injection Combined With AK105 Injection in the Treatment of Advanced Hepatocellular Carcinoma.
- Conditions
- Advanced Hepatocellular Carcinoma
- Interventions
- Drug: TQB2223 injection
- First Posted Date
- 2024-03-20
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 34
- Registration Number
- NCT06320080
- Locations
- 🇨🇳
Affiliated Cancer Hospital of Harbin Medical University, Harbin, Heilongjiang, China
🇨🇳Hubei Provincial Tumor Hospital, Wuhan, Hubei, China
🇨🇳Hunan Provincial Tumor Hospital, Changsha, Hunan, China
TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors.
- Conditions
- Advanced Malignant Neoplasm
- Interventions
- Drug: TQB2928 injection
- First Posted Date
- 2024-03-07
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 3
- Registration Number
- NCT06297642
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing, China
🇨🇳The Second People's Hospital of Hefei, Hefei, Anhui, China
🇨🇳Lu'an People's Hospital of Anhui Province, Lu'an, Anhui, China
Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2023-10-13
- Lead Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- Target Recruit Count
- 72
- Registration Number
- NCT06081673
- Locations
- 🇨🇳
Shanghai Ninth People's Hostipal, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer
- Conditions
- Pancreatic Adenocarcinoma Metastatic
- Interventions
- First Posted Date
- 2023-09-25
- Last Posted Date
- 2023-09-25
- Lead Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Target Recruit Count
- 177
- Registration Number
- NCT06051851
- Locations
- 🇨🇳
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody
- Conditions
- Lung CancerPianzumabTKI ResistanceEGFR Sensitive MutationAnlotinib
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Degan Lu
- Target Recruit Count
- 52
- Registration Number
- NCT06048315
A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2023-08-25
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 75
- Registration Number
- NCT06010901
- Locations
- 🇨🇳
Fuyang Cancer Hospital, Fuyang, Anhui, China
🇨🇳Affiliated Hospital of Jining Medical University, Jining, Shandong, China
🇨🇳Mianyang central hospital, Mianyang, Sichuan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.